MALVERN, Pa., Aug. 7, 2018 /PRNewswire/ -- Realm Therapeutics
plc (NASDAQ: RLM / AIM: RLM), a clinical stage biopharmaceutical
company focused on developing novel therapeutics in immune-mediated
diseases, today announces that the Company will report its first
half 2018 financial results on Tuesday,
August 14, 2018. Realm's management team will host a
conference call and audio webcast at 9:00
a.m. ET / 2:00 p.m. BST on Tuesday,
August 14, 2018 to discuss the financial results and recent
operational highlights.
To access the conference call, please use the dial in details
below:
US Toll-Free: +1
855-857-0686
US Toll: +1 631-913-1422
UK Toll-Free: 08003589473
UK Toll: +44 3333000804
Conference call pin code: 51680194#
Please dial in at least 10 minutes prior to the start time. A
live and archived webcast of this presentation will be available on
the Events and Presentations page of the Company's website,
www.realmtx.com.
About Realm Therapeutics
Realm Therapeutics is a
clinical-stage biopharmaceutical company developing novel
therapeutics that target the interplay between innate and adaptive
immunity. The Company's programs seek to influence immune
signalling and change the course of immune-mediated diseases in
adults and children. Realm's lead drug development program utilizes
the Company's proprietary immunomodulatory technology for the
treatment of Atopic Dermatitis, and the Company is exploring its
efficacy in other dermatology indications which include Acne
Vulgaris, and Psoriasis, as well as other therapeutic areas. For
more information on Realm Therapeutics please visit
www.realmtx.com.
Forward Looking Statements
Certain statements made
in this announcement are forward-looking statements, including with
respect to the Company's clinical trials and product candidate
development plans. These forward-looking statements are not
historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,'
'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,'
and similar expressions are intended to identify forward-looking
statements. These statements are not guarantees of future
performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements, including clinical developments and
regulatory review of product candidates. The Company cautions
shareholders and prospective shareholders not to place undue
reliance on these forward-looking statements, which reflect the
view of the Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
G-RLM
Contacts:
Realm Therapeutics plc
Alex Martin, Chief Executive
Officer
Marella Thorell, Chief Financial
Officer and Chief Operating Officer
Outside US: +44 (0) 20 3727 1000
US: +1 212 600 1902
Argot Partners
Stephanie Marks / Claudia Styslinger
+1 212 600 1902
FTI Consulting
Simon Conway / Mo Noonan
+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer
+44 (0) 20 7496 3000
View original
content:http://www.prnewswire.com/news-releases/realm-therapeutics-to-report-first-half-2018-financial-results-300692771.html
SOURCE Realm Therapeutics